Noninvasive detection of programmed cell loss with 99mTc-labeled annexin A5 in heart failure

Journal of Nuclear Medicine

Volumn 48, Issue 4, 2007, Pages 562-567

  Kietselaer, Bas L J H ^a   Reutelingsperger, Chris P M ^b   Boersma, Hendrikus H ^a   Heidendal, Guido A K ^a   Ing, Han Liem ^c   Crijns, Harry J G M ^a   Narula, Jagat ^d   Hofstra, Leo ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MÁXIMA MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Annexin A5; Apoptosis; Heart failure

Indexed keywords

LIPOCORTIN 5; TECHNETIUM 99M; RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART SCINTISCANNING; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE ANALYSIS; ISOTOPE LABELING; MALE; NON INVASIVE PROCEDURE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BIOLOGICAL MODEL; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; HEART VENTRICLE; METABOLISM; METHODOLOGY; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY;

ADULT; ANNEXIN A5; APOPTOSIS; CARDIOMYOPATHIES; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RADIOPHARMACEUTICALS; TECHNETIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34248586424     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.039453     Document Type: Article

References (26)

1. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation. 2000;102(suppl 4):IV14-IV23.
2. Zhang J, McDonald KM. Bioenergetic consequences of left ventricular remodeling. Circulation. 1995;92:1011-1019.
3. Gomez AM, Valdivia HH, Cheng H, et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science. 1997;276:800-806.
4. Mani K, Kitsis RN. Myocyte apoptosis: programming ventricular remodeling. J Am Coll Cardiol. 2003;41:761-764.
5. Hirota H, Chen J, Betz UA, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189-198.
6. Olivetti G, Abbi R, Quaini F, et al. Apoptosis in the failing human heart. N Engl J Med. 1997;336:1131-1141.
7. Communal C, Sumandea M, de Tombe P, Narula J, Solaro RJ, Hajjar RJ. Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:6252-6256.
8. Hayakawa Y, Chandra M, Miao W, et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galpha(q) transgenic mice. Circulation. 2003;108:3036-3041.
9. Donath S, Li P, Willenbockel C, et al. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation. 2006;113:1203-1212.
10. Webster KA, Bishopric NH. Apoptosis inhibitors for heart disease. Circulation. 2003;108:2954-2956.
11. Fadok VA, Savill JS, Haslett C, et al. Different populations of macrophages use either the vitronectin receptor or the phosphatidylserine receptor to recognize and remove apoptotic cells. J Immunol. 1992;149:4029-4035.
12. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med. 1995;182:1545-1556.
13. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet. 2000;356:209-212.
14. Hofstra L, Dumont EA, Thimister PW, et al. In vivo detection of apoptosis in an intracardiac tumor. JAMA. 2001;285:1841-1842.
15. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347-1352.
16. Chuang ML, Hibberd MG, Salton CJ, et al. Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fraction: assessment by two- and three-dimensional echocardiography and magnetic resonance imaging. J Am Coll Cardiol. 2000;35:477-484.
17. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med. 1996;335:1182-1189.
18. Narula J, Pandey P, Arbustini E, et al. Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. Proc Natl Acad Sci U S A. 1999;96:8144-8149.
19. Narula N, Narula J, Zhang PJ, et al. Is the myofibrillarlytic myocyte a forme fruste apoptotic myocyte? Ann Thorac Surg. 2005;79:1333-1337.
20. Haider N, Narula N, Narula J. Apoptosis in heart failure represents programmed cell survival, not death, of cardiomyocytes and likelihood of reverse remodeling. J Card Fail. 2002;8(6 suppl):S512-S517.
21. Chandrashekhar Y, Narula J. Death hath a thousand doors to let out life. Circ Res. 2003;92:710-714.
22. 99mTc annexin V. J Nucl Med. 1999;40:184-191.
23. Narula J, Southern JF, Dec GW, et al. Antimyosin uptake and myofibrillarlysis in dilated cardiomyopathy. J Nucl Cardiol. 1995;2:470-477.
24. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol. 1992;148:2207-2216.
25. Dumont EA, Reutelingsperger CP, Smits JF, et al. Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med. 2001;7:1352-1355.
26. Obrador D, Ballester M, Carrio I, Berna L, Pons-Llado G. High prevalence of myocardial monoclonal antimyosin antibody uptake in patients with chronic idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1989;13:1289-1293.